

Product Name: Olanzapine Revision Date: 01/10/2021

Product Data Sheet

Olanzapine


Cat. No.: B2240

CAS No.: 132539-06-1 **Formula:** C17H20N4S

M.Wt: 312.43

Synonyms:

Target: Neuroscience
Pathway: 5-HT Receptor
Storage: Store at -20°C



Solvent & Solubility

insoluble in H2O; ≥15.6 mg/mL in DMSO; ≥2.41 mg/mL in EtOH with gentle warming and ultrasonic

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	3.2007 mL	16.0036 mL	32.0072 mL
	5 mM	0.6401 mL	3.2007 mL	6.4014 mL
	10 mM	0.3201 mL	1.6004 mL	3.2007 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Reacting conditions:

Shortsummary	Antagonist of 5-HT2A and dopamine D2 receptors		
IC ₅₀ & Target			
	Cell Viability Assay		
	Cell Line:	U87MG and A172 human glioblastoma cell line	
	Preparation method:	The solubility of this compound in DMSO is >15.6mg/mL. General tips for	
In Vitro		obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes	
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored	
		below -20°C for several months.	

	Applications:	Treatment with olanzapine inhibited the proliferation of established
	Applications.	glioblastoma cell lines and enhanced the antiproliferative effect of
		temozolomide on U87MG and A172 cells. Olanzapine (20 μM, 40 μM) inhibited
		anchorage-independent growth of U87MG cells. Treatment with olanzapine (50
		μM, 100 μM) inhibited the migration of A172MG cells. Olanzapine (144 h)
	010	exerted proapoptotic and necrotizing effects on glioblastoma cell lines.
		Olanzapine yielded a significant cytostatic effect on A172 glioblastoma cells.
	Animal experiment	Section 1
	Animal models:	Rats
	Dosage form:	Subcutaneous injection; 0.5 mg/kg, 3 mg/kg and 10 mg/kg
	Applications:	Olanzapine at 0.5 mg/kg, 3 mg/kg and 10 mg/kg (s.c.) dose-dependently
		increases the extracellular dopamine (DA) and norepinephrine (NE) levels in
In Vivo		rat prefrontal cortex, nucleus accumbens and striatum. Olanzapine also
		increases extracellular levels of a DA metabolite, DOPAC, and tissue
	310	concentrations of a released DA metabolite, 3-methoxytyramine.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may
	Part Control	slightly differ with the theoretical value. This is caused by an experimental
		system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Karpel-Massler G, Kast R E, Westhoff M A, et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect[J]. Journal of neuro-oncology, 2015, 122(1): 21-33.

[2]. Li X M, Perry K W, Wong D T, et al. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum[J]. Psychopharmacology, 1998, 136(2): 153-161.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for

long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APENEIO.

APE BIO

APE BIO

APE BIO

APE BIO

APEVEIO.